| Keratoconjunctivitis Sicca
Restasis vs Lacrisert
Side-by-side clinical, coverage, and cost comparison for keratoconjunctivitis sicca.Deep comparison between: Restasis vs Lacrisert with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLacrisert has a higher rate of injection site reactions vs Restasis based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lacrisert but not Restasis, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Restasis
Lacrisert
At A Glance
Ophthalmic
Twice daily
Calcineurin inhibitor immunosuppressant
Ophthalmic insert
Once daily
Ocular lubricant
Indications
- Keratoconjunctivitis Sicca
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Exposure keratoconjunctivitis
- Corneal hypoesthesia
- Recurrent erosion of cornea
Dosing
Keratoconjunctivitis Sicca Instill one drop twice daily in each eye approximately 12 hours apart; may be used concomitantly with lubricant eye drops, allowing a 15-minute interval between products; discard vial immediately after use.
Dry Eye Syndromes, Keratoconjunctivitis Sicca, Exposure keratoconjunctivitis, Corneal hypoesthesia, Recurrent erosion of cornea One ophthalmic insert in each eye once daily; some patients may require twice daily use for optimal results; insert into the inferior cul-de-sac of the eye beneath the base of the tarsus.
Contraindications
- Known or suspected hypersensitivity to any of the ingredients in the formulation
- Hypersensitivity to hydroxypropyl cellulose
Adverse Reactions
Most common (>=1%) Ocular burning, conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, visual disturbance
Serious Potential for eye injury and contamination
Postmarketing Hypersensitivity (eye swelling, urticaria, angioedema, face swelling, tongue swelling, pharyngeal edema, dyspnea), superficial eye injury
Most common Transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids, hyperemia
Pharmacology
Cyclosporine is an immunosuppressive agent when administered systemically; when applied topically as an ophthalmic emulsion, it is thought to act as a partial immunomodulator in patients whose tear production is suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, though the exact mechanism of action is not known.
Ocular lubricant; stabilizes and thickens the precorneal tear film and prolongs tear film breakup time to reduce signs and symptoms of dry eye syndromes, including lubrication and protection of the eye.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Restasis
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (4/12)
Lacrisert
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Restasis
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (3/8)
Lacrisert
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Restasis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Lacrisert
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Restasis.
No savings programs available for Lacrisert.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RestasisView full Restasis profile
LacrisertView full Lacrisert profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.